OZURDEX® (dexamethasone intravitreal implant) 0.7 mg is a biodegradable implant injected into the eye (vitreous) to treat adults with macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO) and to treat adults with noninfectious uveitis affecting the back segment of the eye.
The OZURDEX® implant is so tiny that it can be injected into the eye (vitreous) with a procedure in your doctor’s office. Each implant is already inside a special applicator device that is needed to perform the insertion. The implant will be injected into the vitreous humor inside your eye. This is known as an intravitreal injection.
Inside the eye, the implant is slowly dissolved by the vitreous gel that fills the eye, releasing medicine to reduce the swelling or inflammation. As the level of medication decreases over time, swelling or inflammation may affect your vision again. If this occurs, your doctor may recommend another OZURDEX® injection.
In 2 clinical studies, 427 patients were treated with OZURDEX® and 426 patients received sham (simulated) injections.
It’s important to remember that each case of retinal vein occlusion is unique. Your own results may vary.
OZURDEX® intravitreal implant has been proven effective for noninfectious uveitis affecting the back segment of the eye in a clinical trial. OZURDEX® helps treat the inflammation causing vitreous haze that is affecting your vision. In a clinical study, 77 patients were treated with OZURDEX® and 76 patients received sham (simulated) injections.
It’s important to remember that each case of noninfectious uveitis affecting the back segment of the eye is unique. Your own results may vary.
Ozurdex is a sustained-release dexamethasone implant that is used in the treatment of various eye conditions, including diabetic macular edema (DME). DME is a complication of diabetic retinopathy, characterized by the accumulation of fluid in the macula, the central part of the retina responsible for sharp, central vision. Ozurdex provides several benefits in the management of DME:
It’s important to note that while Ozurdex can be effective in reducing macular edema associated with DME, it is associated with potential side effects and risks. These may include an increase in intraocular pressure (leading to glaucoma), cataract formation, and the potential for systemic side effects.